• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Rheumatology and Immunology Research

    Rheumatology and Immunology Research

    JournalISSN 2719-4523eISSN 2719-4523

    年发文量

    研究主题

    论文(207)

    排序
    1Chinese Expert Consensus on the Treatment of Immune‑mediated Inflammatory Diseases with Janus Kinase Inhibitors
    Xiaofeng Zeng,Jianzhong Zhang,Minhu Chen

    Abstract In recent years, Janus kinase (JAK) inhibitors have been approved for the treatment of various immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, juvenile idiopathic arthritis, giant cell arteritis, atopic dermatitis, alopecia areata, psoriasis, and inflammatory bowel disease. To standardize the clinical application of JAK inhibitors for IMIDs in China, this consensus group has developed the “Chinese Expert Consensus on the Treatment of Immune-Mediated Inflammatory Diseases with Janus Kinase Inhibitors.” This consensus is formulated based on relevant evidence-based medicine, the latest research data from both domestic and international studies, and the clinical experience of the expert panel. It covers key aspects such as treatment protocols, safety management, and medication use in special patient populations. The aim of this consensus is to assist physicians in making rational clinical decisions regarding the use of JAK inhibitors.

    2026
    引用
    AI阅读
    加入学术空间
    2Popcorn-like Nodules in the Lungs of a Patient with Sjögren’s Disease
    Yuxia Shao, Xiaoshan Yang, Li Li, Li Wang,Yanli Yang
    2026
    引用
    AI阅读
    加入学术空间
    3Disease Burden of Rheumatoid Arthritis in the Context of Population Aging: A Comparative Analysis of China, Japan, the United States and India
    Si Yang,Jiashun Zeng

    Abstract Background and Objectives As worldwide population aging accelerates, the burden of rheumatoid arthritis (RA) continues to increase. This study compared the spatiotemporal trends and underlying drivers of the RA burden across four countries with different levels of socioeconomic development under population aging. Methods Using data from the Global Burden of Disease (GBD) 2021 study, we analyzed age-standardized rates of incidence, prevalence, mortality, and disability-adjusted life years (DALYs) for RA in China, Japan, the United States, and India from 1990 to 2021. Temporal trends were assessed using Joinpoint regression. A decomposition model was applied to quantify the contributions of population growth, population aging, and epidemiological changes to the overall burden. Spearman correlation analysis was performed to evaluate the association between RA burden indicators and the Sociodemographic Index (SDI). The Nordpred model was employed to project age-standardized prevalence rates among individuals aged 60 years and older up to 2046. Results From 1990 to 2021, the numbers of incident cases, prevalent cases, and DALYs attributable to RA increased substantially in China, the United States, and India ( e.g ., prevalent cases in China rose from 2.04 million to 4.76 million, and DALYs increased from 403,000 to 834,000), whereas the corresponding trends in Japan remained relatively stable. Age-standardized DALY rates increased significantly in China and India but exhibited a declining trend in Japan. Decomposition analysis revealed that the rise in RA burden in China was jointly driven by population aging and population growth, while in Japan, population aging alone accounted for nearly the entire increase. RA prevalence showed a strong positive correlation with SDI ( r = 0.82, P < 0.001). Projections indicate that by 2046, the age-standardized prevalence of RA among older adults will continue to rise in China, the United States, and India, whereas Japan is expected to reach a plateau. Conclusion The burden of RA remains substantial in China, the United States, and India, and has shown a continuous upward trend, with older women being at particularly high risk. Population aging and population growth are the main driving factors. These findings highlight the need to establish a targeted comprehensive prevention and control system for RA among older adults and formulate differentiated, forward-looking health policies aligned with population aging trends to mitigate the future disease burden.

    2026
    引用
    AI阅读
    加入学术空间
    4Salivary Gland and Hand Involvement in Systemic Sclerosis: A Cross-Sectional Ultrasound and Radiographic Study
    Theau Cavillon,François Zimmermann,Nicolas Belhomme,Guillaume Coiffier,Pascal Guggenbuhl,Alain Lescoat,François Robin
    2026
    引用
    AI阅读
    加入学术空间
    5Economic Burden and Quality of Life of IgG4-related Disease in China: A Comparative Analysis of Three Treatment Regimens
    Yifei Wang, Jialing Jiang,Yuxue Nie, Jingna Li, Jialei Zhang, Qinhuan Luo, Xinli Yang,Nianyi Zhang, Shuo Liu, Jueming Lei,Jiaxin Zhou,Yunyun Fei,

    Abstract Background and Objectives IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder requiring prolonged treatment, placing substantial financial burden on patients. This study compares the direct medical costs of three treatment regimens—glucocorticoid (GC), GC combined with Mycophenolate mofetil (MMF), and rituximab (RTX) —and evaluates the patients’ health-related quality of life (HR-QoL) using the EuroQol 5-Dimension 5-Level scale (EQ-5D-5 L) to assess cost-effectiveness. Methods Our retrospective cohort study consecutively distributed EQ-5D-5 L questionnaires to treatment-naïve IgG4-RD outpatients. Patients formed three cohorts: 30 with GC, 30 with GC+MMF, and 20 with RTX. Patients on other regimens were excluded. HR-QoL was assessed using EQ-5D-5 L questionnaires and visual analog scales. Quality-adjusted life years (QALYs) were calculated, and incremental cost-effectiveness ratios were computed. Probabilistic sensitivity analysis with Monte Carlo simulations evaluated cost-effectiveness across willingness-to-pay thresholds. Results First-year treatment costs were $1284.53 for GC, $2090.96 for GC+MMF, and $6175.97 for RTX. RTX group demonstrated the lowest relapse rate. No significant differences were observed in HR-QoL scores among groups, though visual analog scale (VAS) scores favored GC over GC+MMF. Median incremental cost-effectiveness ratios of probabilistic sensitivity analysis were $13,310/QALY for RTX versus GC and $17,412/QALY for RTX versus GC+MMF. GC demonstrated highest cost-effectiveness probability at willingness-to-pay thresholds below $15,000/QALY. Inverse probability of treatment weighting analysis confirmed these findings’ robustness after controlling for selection bias. Conclusions While RTX offers superior efficacy with lowest relapse rates, its high price leads to limited usage in China. GC-based regimens provide reasonable outcomes at lower costs, making GC or GC+MMF more economical choices.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 207 篇论文

    高被引作者

    作者引用发文
    Xiaofeng Zeng53831
    Mengtao Li50725
    Xinping Tian44521
    Qian Wang40618
    Yaolong Chen3594
    Cibo Huang3585
    Huji Xu3566
    Zhiyi Zhang3474
    yan zhao3456
    Junqiang Lei3432

    高产作者

    作者引用发文
    Xiaofeng Zeng53831
    Mengtao Li50725
    Jiuliang Zhao13123
    Xinping Tian44521
    Qian Wang40618
    Marco Matucci Cerinic910
    Qingping Yao447
    Dong Xu246
    Saba Samreen206
    yan zhao3456

    相关期刊

    暂无数据
    暂无数据